Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus
Description:
<p>Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon λ3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that <sub>rs12979860</sub> strikingly determined the first phase of viral elimination (P <.001). In patients treated for 24 weeks, <sub>rsl2979860</sub> also predicted the rate of sustained virologie response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CC <sub>rs12979860</sub> had higher baseline HCV RNA levels (P <.001) and did not, when treated for 12 weeks, achieve sustained virologie response more often than those carrying CTrs or Tl <sub>rs12979S6</sub> . The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.</p>